Inspirata Acquires Precision Medicine Network, Inc. and the ‘Crosswalk’ Platform to Bridge the Gap Between Digital Pathology and Molecular Oncology
“Crosswalk Insight™: Oncology” enhances Inspirata’s Digital Pathology Cockpit by providing access to Genomic Profiles, FDA-Approved Targeted Therapies, Immunotherapies and Clinical Trials to enable pathologists to make more precise diagnostic and therapeutic decisions.
Tampa, FL, September 13, 2016 – Cancer diagnostics and digital pathology workflow solution provider Inspirata, Inc. announced today that it has acquired the assets of Boston-based Precision Medicine Network™, Inc., including its products and the associated intellectual property. This includes “Crosswalk Insight: Oncology” (Crosswalk), a precision medicine knowledge visualization and decision support platform. Inspirata plans to integrate Crosswalk with its Digital Pathology Cockpit and its Cancer Information Data Trust (CIDT) to enhance the precision medicine tools and services available in these products.
When a cancer center engages Inspirata for an end-to-end digital pathology workflow solution, each pathologist at the institution receives a Digital Pathology Cockpit, which provides single-sign-on access to all of the patient’s institution-based diagnostic data, including Whole Slide Images (WSI). This enables pathologists to quickly gain insights about the patient’s history so they can work faster and make better informed decisions. With the addition of Crosswalk these capabilities are extended to encompass actionable multidisciplinary medical data, comprising genomic profiles, clinical trials and personalized therapies. Crosswalk aggregates this information in a cloud-based platform with an intuitive user interface for easy access and navigation.
According to Precision Medicine Network’s Co-founder and Chief Medical Officer, Mark Boguski, MD, PhD, “The rapid pace of discovery and change in cancer diagnosis and care has created a pervasive knowledge gap between what is possible and what is actually available for precision diagnosis and personalized treatment inside a healthcare system. Through Crosswalk, we’ve been able to connect our users to information about disease types, biomarkers and companion diagnostics, molecular biological pathways, as well as available drugs and clinical trials. When pathologists have this information at their fingertips in Inspirata’s Digital Pathology Cockpit, they will be able to provide a more precise diagnosis and recommend treatment options tailored to the individual patient. Precision diagnosis is a critical component of precision medicine and an essential contributor to value-based care.”
“Precision Medicine Network is a very strategic acquisition for us because the Crosswalk platform positions our Digital Pathology Cockpit to bridge the gap between anatomic pathology and a patient’s tumor genes, molecular pathways, matching drugs and relevant drug trials that they may be eligible for,” says Inspirata CEO Satish Sanan.
Dr. Boguski will join Inspirata as Senior Vice President of Precision Medicine and also will be a member of its Strategic Advisory Board. “In this role,” continues Sanan, “Dr. Boguski will provide insights for our joint vision for precision medicine as well as the integration of the Crosswalk platform into the Inspirata Digital Pathology Cockpit and CIDT. He is a medical scientist who brings a wealth of knowledge and expertise to this role, including experience as an executive in the biotechnology and pharmaceutical industries. He is a true visionary in the field of precision medicine and a pioneer in the fields of biomedical informatics and genomics. He is a member of the U.S. National Academy of Medicine and has held faculty positions at Harvard Medical School, the Johns Hopkins University School of Medicine, the U.S. National Institutes of Health, and the U.S. National Library of Medicine. We are delighted that Dr. Boguski will be joining Inspirata’s executive leadership team.”
About Precision Medicine Network, Inc.
Precision Medicine Network™ was co-founded in 2011 by Richard Kellner, CEO, and Dr. Mark Boguski, CMO. PMNI was an outgrowth of the Genomic Medicine Initiative at Harvard Medical School in 2009. The company’s mission is to provide “Fluency in the language of Precision Medicine™” as a basis of connecting providers, patients and payers to overcome barriers and realize the potential of precision healthcare. This is accomplished through “Crosswalk Insight™: Oncology,” a platform designed to accelerate the rational adoption of precision medicine. Current users of the system include medical, surgical and radiation oncologists, pathologists and laboratory medicine professionals, pharmaceutical companies, clinical trial developers, diagnostics companies, life science toolmakers, health system executives, medical students, residents and fellows, and oncology nurses and genetic counselors. For more information, visit http://www.precisionready.com/.
About Inspirata, Inc.
Inspirata™, Inc. provides a cancer diagnostics solution that digitizes and automates the entire pathology workflow using a unique, “solution as a service” delivery model. This comprehensive solution helps to solve interoperability issues, and includes workflow automation and diagnostic tools to help pathologists work more efficiently. Inspirata’s diagnostic tools include algorithms that extract relevant image-based information from digitized histology specimens for use as supplemental screening aids to assist pathologists with cancer detection and prediction of disease progression and therapeutic responses. For more information, please visit http://www.inspirata.com/ or contact info@inspirata.com.
All trademarks used herein are the property of their respective owners.
Source: Inspirata
